On October 29, 2024, we hosted the Scientific Advisory Board (SAB) Meeting at Biozentrum, University of Basel. It was a moment to reflect on a year of progress, research, and collective effort in advancing multiple sclerosis (MS) research.
A heartfelt thank you to our dedicated speakers and the entire team who showcased their work through engaging presentations. The feedback from our Advisory Board was immensely positive, emphasizing their encouragement for the strides we've made in translational research.
What sets RC2NB apart is the unique research environment in Basel. Here, a powerful combination of well-defined patient cohorts, a strong clinical trial framework, and advanced tools for clinical phenotyping converge seamlessly. Add to that our state-of-the-art neuroimaging techniques, biomarker analysis, and precise immunological monitoring of therapies, and you have a setting primed for advancements.
This meeting reinforced what we already knew: impactful research thrives where expertise, technology, and dedication meet. Thank you to everyone who participated, contributed, and made this milestone possible.
Looking forward to more research and continued innovation in the year ahead!
